Dr. Shu Fang Liu graduated from Shanghai Second Medical University in China and received his PhD in Molecular Pharmacology from Imperial College, University of London, England. He is currently associate investigator at the Feinstein Institute for Medical Research and professor of medicine at Hofstra NS-LIJ School of Medicine. Dr. Liu has been investigating the molecular and cellular mechanisms of multiple organ injury caused by sepsis, a condition that claimed thousands of lives each year for 20 years.

The goal of Dr. Liu’s proposed research is to investigate the signaling pathways in myeloproliferative diseases over the course of the disease. Understanding these mechanisms may allow for the development of more efficacious and better targeted therapies. This approach requires samples from individual patients with myeloproliferative diseases. He has the expertise, leadership and motivation necessary to successfully carry out the proposed work. He has over 20 years experience focusing on the treatment of hematologic malignancies. He has served as principal ivestigator or co-investigator for many clinical trials involving the treatment of patients with myelodysplastic syndrome and leukemia including studies involving close collaboration between the clinician and basic science laboratory. This has been done with great success in chronic lymphocytic leukemia where serial samples over time have been obtained and studied in collaboration with basic science laboratories.

Dr. Liu has been an active member of the National Cancer Institute sponsored Community Clinical Oncology Program participating in multiple cooperative group clinical trials for patients with hematologic malignancies. He successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers and produced over 100 peer-reviewed publications based upon these projects. As a result of his previous experience, he is aware of the requirements to successfully undertake a clinical trial following good clinical practice guidelines.

His laboratory focuses on molecular mechanisms of septic shock, and septic multiple organ injury (MOI), conditions that claim thousands of life each year. Using modern molecular biology techniques, his team is identifying the molecular events that take place when bacterial infections initiate the inflammatory process and lead to the development of septic shock and septic MOI. The purpose of his research is to discover new targets for novel therapies for treating this life-threatening condition. He has recently discovered that in addition to triggering uncontrolled systemic inflammation, bacterial infection also suppresses the expression of multiple “housekeeping genes”, whose products are critical for the maintenance of normal organ functions, and impairs our body’s anti-inflammatory and protective mechanisms.

Dr. Liu and his team are investigating how bacterial infection represses housekeeping gene expression and impairs the anti-inflammatory and protective mechanisms, and are trying to find the ways of boost these anti-inflammatory and protective mechanisms. Their recent studies have also demonstrated that endothelial-targeted blockade of inflammatory pathways can effectively prevent septic MOI, while avoiding the impairment of our body’s host defense capability, a serious side-effect commonly seen in systemic inhibition of inflammatory pathways. This may lead to the development of novel anti-sepsis therapies.

Xiaobing Ye
Phone: (516) 562-1604
Email: xye@nshs.edu

Shanghai Second Medical University, China
Degree: BM
1977
Field of Study: Medicine

Wenzhou Medical College, China
Degree: MS
1982
Field of Study: Cardiovascular Diseases

Imperial College, University of London, England
Degree: PhD
1993
Field of Study: Molecular Pharmacology

National Heart & Lung Institute, University of London, England
Degree: Postdoctoral
1995
Field of Study: Molecular Pharmacology

1988 Scientific Achievement Award, Third Place, Zhejiang Province, China.
1989 Scientific Achievement Award, First Place, Wenzhou City, Zhejiang, China.
1990 Science and Technology Advance Award, NanShi Foundation, Hong Kong.
1990 Predoctoral Fellowship, British Heart Foundation.
1990 Overseas Research Student Award, British Council, United Kingdom.
1991 Overseas Research Student Award, British Council, United Kingdom.
1992 Overseas Research Student Award, British Council, United Kingdom.
1992 Winner of Best Scientific Paper, Guanghua Foundation.
1993 Postdoctoral Fellowship, British Heart Foundation.

1. Fang, G, Song, D., Ye, X, Mao, S-Z, Liu, G, and Liu SF. “Chronic Intermittent Hypoxia Exposure Induces Atherosclerosis in ApoE Knockout Mice: Role of NF-κB p50.” Am J Pathol. 181:1530-9, 2012).
2. Song, D, Fang, G, Mao, SZ, Ye, X, Liu, G, Gong, Y and Liu SF. “Chronic intermittent hypoxia induces atherosclerosis by NF-κB-dependent mechanisms.” Biochim Biophys Acta Mol Dis. 1822:1650-9, (2012).
3. Xu, H, Ye, X, Steinberg, H and Liu SF. “Selective blockade of endothelial NF-kappaB pathway differentially affects systemic inflammation and multiple organ dysfunction and injury in septic mice.” J Pathol 220:490-498, 2010.
4. Song, D., Ye, X., Xu, H., Zhu, S. and Liu, S.F. ”Activation of endothelial intrinsic NF-κB pathway impairs protein C anticoagulation mechanism and promotes coagulation in endotoxemic mice.” Blood, 114: 2521-2529, 2009.
5. ing, J., Ye, X., Song, D., and Liu, S.F. ”A pivotal role of endothelial-specific NF-κB signaling in the pathogenesis of septic shock and septic vascular dysfunction.” J. Immunol. J. 183: 4031 – 4038, 2009.
6. Ye, X., Ding, D., Zhou, Z., Chen, G. and Liu, S.F. “Divergent roles of endothelial NF-κB in multiple organ injury and bacterial clearance in murine models of sepsis.” J. Exp. Med. 205:1303-1315 2008.

View more at PubMed